The Boston Globe Names C4 Therapeutics a Top Place to Work for 2017

CAMBRIDGE, Mass. – C4 Therapeutics (C4T) has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey project from The Boston Globe.

Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees. The survey measures employee opinions about their company’s direction, execution, management, pay and benefits, and engagement.

The employers are placed into one of four groups: small, with 50 to 99 employees; medium, with 100 to 249 workers; large, with 250 to 999; and largest, with 1,000 or more.

C4T was ranked #13 in the small workplace category. The company offers numerous progressive benefits to their 59 employees, including flexible vacation time, visa sponsorships, break rooms stocked with free beverages and snacks, active women’s group, regular social hours, wellness and flexible spending account subsidies and more. 

“It is an incredible honor to be recognized by The Boston Globe on this year’s Top Places to Work,” said Andy Phillips, President and Chief Scientific Officer of C4 Therapeutics. “C4T employs some of the brightest and most motivated people in the life sciences industry. We are committed to an environment that both attracts top talent and that provides a fun, engaging, and rewarding place to pursue the development of novel approaches for treatment of human disease.”

The rankings in the Top Places to Work are based on confidential survey information collected by Energage (formerly WorkplaceDynamics), an independent company specializing in employee engagement and retention, from nearly 75,060 individuals at 334 Massachusetts organizations.

About Boston Globe Media Partners, LLC

Boston Globe Media Partners, LLC provides news and information, entertainment, opinion and analysis through its multimedia properties. BGMP includes the Boston Globe,,, STAT and Globe Direct.

About C4 Therapeutics

C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders. To learn more about C4 Therapeutics, visit

Media Contact:

MacDougall Biomedical Communications
Kari Watson or Kara Mazey
781-235-3060 or